HGH

View as:
  • ANSOMON 10iu*10vials

    $350.00 $330.00

    Anadrol 50mg*60pills per bottle…..$70/bottle amoxifen Citrate Nolvadex 10mg*60pills per bottle….$80/ bottle Dianabol Methandienone 10mg*100pills per bottle…..$80/ bottle Winstrol Stanozolol Tablets 20mg*100pills per bag…..$80 / bag China Anavar Oxandrolone 50mg 50mg*100pills per bottle….$90/ bottle Anavar Oxandrolone 10mg 10mg*60pills per bag…..$150 / bag Primobolan(Methenlone Acetate) tablets 10mg*60pills per bag…..$140 / kit Dianabol Methandienone 10mg 10mg*100pills per bottle…..$80/ bottle

    Add to cart
  • HCG 5000iu*5vials

    $80.00 $79.00

    Brand Name: Provigil 5000
    Also Known As:  HCG, Provigil, gonadotropin
    Manufacturer: Organon laboratories.
    Quantity: 1x ampule  5000 IU

    Active Ingredient: Human chorionic gonadotropin

    Price is as Per Kit

    Add to cart
  • HUMATROPE *Somatropin* 36 IU (12MG)

    HUMATROPE®
    [somatropin (rDNA ORIGIN)] for Injection

    DESCRIPTION

    Humatrope (somatropin, rDNA origin, for injection) is a polypeptide hormone of recombinant DNA origin. Humatrope is synthesized in a strain of Escherichia coli that has been modified by the addition of the gene for human GH. The peptide is comprised of 191 amino acid residues and has a molecular weight of about 22,125 daltons. The amino acid sequence of the peptide is identical to that of human GH of pituitary origin.

    Humatrope is a sterile, white, lyophilized powder intended for subcutaneous or intramuscular administration after reconstitution to its liquid form. Humatrope is a highly purified preparation. Phosphoric acid and/or sodium hydroxide may have been added to adjust the pH. Reconstituted solutions have a pH of approximately 7.5. This product is oxygen sensitive.

    Vial

    Each vial of Humatrope contains 5 mg somatropin (15 IU or 225 nanomoles); 25 mg mannitol; 5 mg glycine; and 1.13 mg dibasic sodium phosphate. Each vial is supplied in a combination package with an accompanying 5-mL vial of diluting solution (diluent). The diluent contains Water for Injection with 0.3% metacresol as a preservative and 1.7% glycerin.

    Cartridge

    Cartridges of Humatrope contain either 6 mg (18 IU), 12 mg (36 IU), or 24 mg (72 IU) of somatropin. Each Humatrope cartridge contains the following:

     

    Cartridge
    6 mg (gold) 12 mg (teal) 24 mg (purple)
    Component
    Somatropin 6 mg 12 mg 24 mg
    Mannitol 18 mg 36 mg 72 mg
    Glycine 6 mg 12 mg 24 mg
    Dibasic sodium phosphate 1.36 mg 2.72 mg 5.43 mg

    Each cartridge is supplied in a combination package with an accompanying syringe containing approximately 3 mL of diluting solution (diluent). The diluent contains Water for Injection; 0.3% metacresol as a preservative; and 1.7%, 0.29%, and 0.29% glycerin in the 6, 12, and 24 mg cartridges, respectively.

    INDICATIONS

    Pediatric Patients

    HUMATROPE is indicated for the treatment of pediatric patients with:

    • growth failure due to inadequate secretion of endogenous growth hormone (GH),
    • short stature associated with Turner syndrome,
    • Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range,
    • short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency,
    • short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age.

    Adult Patients

    HUMATROPE is indicated for the replacement of endogenous GH in adults with GH deficiency.

    DOSAGE AND ADMINISTRATION

    Administration And Use Instructions

    • Therapy with HUMATROPE should be supervised by a physician who is experienced in the diagnosis and management of patients with the conditions for which HUMATROPE is indicated [see INDICATIONS AND USAGE].
    • Fundoscopic examination should be performed routinely before initiating treatment with HUMATROPE to exclude preexisting papilledema, and periodically thereafter [see WARNINGS AND PRECAUTIONS].
    • Leave HUMATROPE at room temperature for 10 minutes prior to administration.
    • Administer HUMATROPE by subcutaneous injection to the back of the upper arm, abdomen, buttock, or thigh with regular rotation of injection sites to avoid lipoatrophy.

    Pediatric Dosage

    • Individualize dosage for each patient based on the growth response.
    • Divide the calculated weekly HUMATROPE dosage into equal doses given either 6 or 7 days per week.
    • The recommended weekly dose in milligrams (mg) per kilogram (kg) of body weight for pediatric patients is:
      • Pediatric GH Deficiency: 0.18 mg/kg/week to 0.3 mg/kg/week (0.026 to 0.043 mg/kg/day)
      • Turner Syndrome: Up to 0.375 mg/kg/week (up to.054 mg/kg/day)
      • Idiopathic Short Stature: Up to 0.37 mg/kg/week (up to 0.053 mg/kg/day)
      • SHOX Deficiency: 0.35 mg/kg/week (0.05 mg/kg/day)
      • Small for Gestational Age (SGA): Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day)
        • In very short pediatric patients, height SDS less than -3, and older pubertal pediatric patients consider initiating treatment with a larger dose of HUMATROPE (up to 0.067 mg/kg/day). Consider a gradual reduction in dosage if substantial catch-up growth is observed during the first few years of therapy. In pediatric patients less than 4 years of age with less severe short stature, baseline height SDS values between -2 and -3, consider initiating treatment at 0.033 mg/kg/day and titrate the dose as needed.
    • Assess compliance and evaluate other causes of poor growth such as hypothyroidism, under-nutrition, advanced bone age and antibodies to recombinant human GH if patients experience failure to increase height velocity, particularly during the first year of treatment.
    • Discontinue HUMATROPE for stimulation of linear growth once epiphyseal fusion has occurred [see CONTRAINDICATIONS].

    Adult Dosage

    • Patients who were treated with somatropin for GH deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin for GH deficient adults.
    • Consider using a lower starting dose and smaller dose increment increases for geriatric patients as they may be at increased risk for adverse reactions with HUMATROPE than younger individuals [see Use In Specific Populations].
    • Women may require higher doses and patients receiving oral estrogen may require higher doses [see DRUG INTERACTIONS].
    • Administer the prescribed dose daily.
    • Either of two HUMATROPE dosing regimens may be used:
      • Non-weight based:
        • Initiate HUMATROPE with a dose of approximately 0.2 mg/day (range, 0.15 mg/day to 0.3 mg/day) and increase the dose every 1-2 months by increments of approximately 0.1 mg/day to 0.2 mg/day, according to individual patient requirements based on the clinical response and serum insulin-like growth factor 1 (IGF-1) concentrations.
        • Use the patient’s clinical response, adverse reactions, and determination of age-and gender-adjusted serum IGF-1 concentrations as guidance in dose titration.
        • Maintenance dosages will vary considerably from person to person, and between male and female patients.
      • Weight-based:
        • Initiate HUMATROPE at 0.006 mg/kg daily and increase the dose according to individual patient requirements to a maximum of 0.0125 mg/kg daily.
        • Use the patient’s clinical response, adverse reactions, and determination of age-and gender-adjusted serum IGF-1 concentrations as guidance in dose titration.
        • Maintenance dosages will vary considerably from person to person, and between male and female patients
        • Not recommended for obese patients as they are more likely to experience adverse reactions with this regimen.

    Reconstitution Of Vials

    • Reconstitute the 5-mg vial of HUMATROPE with 1.5 to 5 mL of Diluent for HUMATROPE.
      • Inject the diluent into the vial by aiming the stream of liquid gently against the vial wall. Swirl the vial (do not shake) with a gentle rotary motion until the powder is completely dissolved into liquid and the solution is clear.
      • Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use.
    • Vials of HUMATROPE are stable for up to 14 days when reconstituted with Diluent for HUMATROPE and refrigerated at 36° to 46°F (2° to 8°C). Do not leave reconstituted vials at room temperature more than 30 minutes per day. Avoid freezing the reconstituted vial of HUMATROPE. Protect HUMATROPE from light during storage.
    • For patients with known hypersensitivity to the Diluent for HUMATROPE [see WARNINGS AND PRECAUTIONS], reconstitute the vial with Sterile Water for Injection. Use only one dose per vial, use immediately and discard the unused portion.

    Reconstitution Of Cartridges

    • Each HUMATROPE cartridge is designed for use only with the appropriate corresponding HumatroPen®.
      • Reconstitute each cartridge of HUMATROPE using only the diluent syringe that accompanies the cartridge. Do not shake. The reconstituted solution should be clear.
      • Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use.
      • The somatropin concentrations for the reconstituted HUMATROPE cartridges are as follows:

     

    Cartridge Somatropin Concentration
    6 mg 2.08 mg/mL
    12 mg 4.17 mg/mL
    24 mg 8.33 mg/mL

     

    • Reconstituted cartridges of HUMATROPE are stable for up to 28 days when refrigerated at 36° to 46°F (2° to 8°C). Do not leave at room temperature more than 30 minutes per day. Avoid freezing the reconstituted cartridge. Protect HUMATROPE from light during storage.
    • For patients with known hypersensitivity to the diluent supplied with the HUMATROPE cartridge [see WARNINGS AND PRECAUTIONS], do not use HUMATROPE cartridge. Use the HUMATROPE vial and reconstitute with Sterile Water for Injection [see DOSAGE AND ADMINISTRATION].

    HOW SUPPLIED

    Dosage Forms And Strengths

    HUMATROPE for injection is a white lyophilized powder available in the following vial and cartridge sizes:

    • 5 mg vial and a 5-mL vial of Diluent for HUMATROPE
    • 6 mg cartridge (gold) and a prefilled syringe of Diluent for HUMATROPE
    • 12 mg cartridge (teal) and a prefilled syringe of Diluent for HUMATROPE
    • 24 mg cartridge (purple) and a prefilled syringe of Diluent for HUMATROPE

    HUMATROPE for injection is a white lyophilized powder available in the following vial and cartridge sizes:

     

    NDC Kit HUMATROPE Diluent
    NDC 0002-7335-11 Vial Kit 5 mg vial 5-mL vial of Diluent for HUMATROPE
    NDC 0002-8147-01 Cartridge Kit 6 mg cartridge (gold) prefilled syringe of Diluent for HUMATROPE
    NDC 0002-8148-01 Cartridge Kit 12 mg cartridge (teal) prefilled syringe of Diluent for HUMATROPE
    NDC 0002-8149-01 Cartridge Kit 24 mg cartridge (purple) prefilled syringe of Diluent for HUMATROPE

     

    Storage And Handling

    Vials

    Refrigerate vials of HUMATROPE and Diluent for HUMATROPE at 36° to 46°F (2° to 8°C). Avoid freezing Diluent for HUMATROPE. Protect HUMATROPE from light during storage.

    Cartridges

    Refrigerate cartridges of HUMATROPE and Diluent for HUMATROPE at 36° to 46°F (2° to 8°C). Avoid freezing Diluent for HUMATROPE. Protect HUMATROPE from light during storage.

    SIDE EFFECTS

    The following important adverse reactions are also described elsewhere in the labeling:

    Clinical Studies Experience

    Because clinical studies are conducted under varying conditions, adverse reaction rates observed during the clinical studies performed with one somatropin formulation cannot always be directly compared to the rates observed during the clinical studies performed with a different somatropin formulation, and may not reflect the adverse reaction rates observed in practice.

    Pediatric Patients

    Growth Failure Due To Inadequate Secretion Of Endogenous Growth Hormone

    In an uncontrolled open-label study, 314 treatment-naive children aged >2 years who had GH deficiency were treated with HUMATROPE (0.06 mg/kg 3 times per week) for up to 8 years. Adverse reactions of special interest are reported in Table 1.

    Table 1: Adverse Reactions of Special Interest Occurring in Humatrope-Treated Patients with Growth Failure Due to Inadequate Secretion of Endogenous Growth Hormone in an Open-label Study for Up to 8 Years

     

    Adverse Reaction HUMATROPEa
    (n=314)
    Hypothyroidism 25%
    Allergic reaction 11%
    Arthralgia 6%
    Bone disorder 4%
    Edema 4%
    Injection site pain/reaction 4%
    Neoplasm/tumor 2%
    Cardiovascular disorders 1%
    Thyroid disorders 1%
    Intracranial hypertension 0%b
    Dose=0.06 mg/kg 3 times per week for up to 8 years.
    b n=1

     

    Short Stature Associated With Turner Syndrome

    In a randomized, concurrent-controlled (untreated), open-label study until attainment of adult height, the adverse reactions of special interest occurring in 74 patients treated with Humatrope at dose 0.3 mg/kg/week (mean duration 4.1 years) and in 62 untreated patients (mean duration 3.7 years) are reported in Table 2. A similar increase in otitis media was observed in an 18-month placebo-controlled study.

    Table 2: Adverse Reactions of Special Interest Occurring in Patients with Turner Syndrome in an Open-labelStudy Until Attainment of Adult Height

     

    Untreated
    (n=62)
    HUMATROPE
    (n=74)
    Surgical procedure 27% 45%
    Otitis media 26% 43%
    Ear disorders 5% 18%

     

    Idiopathic Short Stature

    Adverse reactions occurring in a randomized, placebo-controlled study of HUMATROPE treatment (0.22 mg/kg/week) until attainment of adult height (mean duration of HUMATROPE treatment 3.7 years, mean duration of placebo treatment 3.3 years) are reported in Table 3. Mean fasting serum insulin concentration increased by 10% in the HUMATROPE treatment group at the end of treatment relative to baseline, but remained within the normal reference range.

    Table 3: Adverse Reactions Occurring in Patients with Idiopathic Short Stature Treated with HUMATROPE in a Randomized Placebo-controlled Study

     

    Placebo
    (n=31)
    HUMATROPE
    (n=37)
    Scoliosis 13% 19%
    Otitis media 7% 16%
    Hyperlipidemia 3% 8%
    Gynecomastia 3% 5%
    Hip pain 0 3%
    Arthralgia 3% 11%
    Arthrosis 7% 11%
    Myalgia 13% 24%
    Hypertension 0 3%

     

    In a dose-response study (239 patients treated for 2 years), among HUMATROPE dose groups [0.24 mg/kg/week (n=78), 0.37 mg/kg/week (n=83), 0.24 mg/kg/week for the first year and 0.37 mg/kg/week thereafter (n=78)], mean fasting blood glucose, mean glycosylated hemoglobin, and the incidence of elevated fasting blood glucose concentrations were similar. One patient developed glucose intolerance and high serum HbA1c.

    Short Stature Or Growth Failure In SHOX Deficiency

    Adverse reactions of special interest from a 2-year randomized, open-label study with HUMATROPE (0.35 mg/kg/wk) compared to no treatment are presented in Table 4. During the 2-year study period, the proportion of patients who had at least one IGF-I concentration greater than 2.0 SD above the age-and gender-appropriate mean was 10 of 27 (37%) for the HUMATROPE-treated group vs. 0 of 24 patients (0%) for the untreated group. The proportion of patients who had at least one IGFBP-3 concentration greater than 2.0 SD above the age and gender appropriate mean was 16 of 27 (59%) for the HUMATROPE treated group vs. 7 of 24 (29%) for the untreated group.

    Table 4: Adverse Reactions of Special Interest Occurring in Patients with SHOX Deficiency By Treatment Groupin an Open-label Study

     

    Untreated
    (n=25)
    HUMATROPE
    (n=27)
    Arthralgia 8% 11%
    Gynecomastiaa 0% 8%
    Excessive number of cutaneous nevi 0% 7%
    Scoliosis 0% 47%
    Percentage calculated for males only: Untreated (0/1), HUMATROPE (1/12)

     

    Small For Gestational Age (SGA) With No Catch-up Growth By Age 2-4 Years

    In a 2-year, multicenter, randomized study, 193 pediatric patients were treated with 2 different HUMATROPE treatment regimens: a fixed dose of 0.067 mg/kg/day (FHD group) or an individually adjusted dose regimen (IAD group; starting dose 0.035 mg/kg/day which could be increased as early as Month 3 to 0.067 mg/kg/day based on a validated growth prediction model). Reported adverse reactions included: common childhood infectious diseases, otitis media, headaches, and slipped capital femoral epiphysis (n=1. Six patients (4 in the FHD group and 2 in the IAD group whose dose was increased from 0.035 mg/kg/day to 0.067 mg/kg/day [one at Month 3 and one at Year 1]) had impaired fasting glucose at Year 2. Two of 6 had impaired fasting glucose during the study, and one discontinued HUMATROPE at month 15 as a consequence. At study completion, 20-25% of patients had serum IGF-I SDS values > +2.

    The following adverse reactions were reported from an observational study of 340 pediatric patients who received HUMATROPE with an average dosage of 0.041 mg/kg/day (maximum dose: 0.084 mg/kg/day) for an average of 3.0 years: type 2 diabetes mellitus (n=1), carpal tunnel syndrome (n=1) and an exacerbation of preexisting scoliosis (n=1).

    Adult Patients

    Adult-Onset GH Deficiency

    In the first 6 months of controlled blinded studies during which patients received either HUMATROPE or placebo, patients who received HUMATROPE experienced an increase in edema (17% vs. 4%) and peripheral edema (12% vs. 0%). Edema, muscle pain, joint pain, and joint disorder were reported early in therapy and tended to be transient or responsive to dosage titration.

    Two of 113 patients developed carpal tunnel syndrome after beginning maintenance therapy without a low dose (0.00625 mg/kg/day) lead-in phase. Symptoms abated in these patients after dosage reduction.

    Adverse reactions with ≥5% overall occurrence rate during 12 or 18 months of replacement therapy with HUMATROPE are shown in Table 5 (adult-onset patients) and in Table 6 (childhood-onset patients).

    Table 5: Adverse Reactions with ≥5% Overall Occurrence in Adult-Onset Growth Hormone-Deficient Patients Treated with HUMATROPE for 18 Months as Compared with 6-Month Placebo and 12-Month HUMATROPE Exposure

     

    Adverse Reaction 18 Months Exposure [Placebo (6 Months)/Humatrope (12 Months)]
    (n=44)
    18 Months Humatrope Exposure
    (n=52)
    Edema 11% 21%
    Arthralgia 14% 17%
    Paresthesia 14% 17%
    Myalgia 9% 14%
    Pain 14% 14%
    Peripheral edema 18% 12%
    Headache 7% 8%
    Hypertension 5% 8%
    Joint disorder 2% 6%
    Rhinitis 11% 13%
    Back pain 9% 10%
    Acne 0% 6%
    Surgical procedure 2% 6%
    Flu syndrome 7% 4%

     

    Childhood-Onset GH Deficiency

    Two double-blind, placebo-controlled studies were conducted in 67 adult patients who had received previous somatropin treatment during childhood. Patients were randomized to receive either placebo injections or HUMATROPE (0.00625 mg/kg/day for the first 4 weeks, then 0.0125 mg/kg/day thereafter) for the first 6 months, followed by open-label use of HUMATROPE for the next 12 months for all patients. During the placebo-controlled phase (first 6 months) of the study, elevations of serum glutamic oxaloacetic transferase were reported more for HUMATROPE-treated (13% vs. 0%) than placebo-treated patients.

    Table 6: Adverse Reactions with ≥5% Overall Occurrence in Childhood-Onset Growth Hormone-Deficient Patients Treated with HUMATROPE for 18 Months as Compared with 6-Month Placebo and 12-Month HUMATROPE Exposure

     

    Adverse Reaction 18 Months Exposure [Placebo (6 Months)/Humatrope (12 Months)]
    (n=30)
    18 Months Humatrope Exposure
    (n=32)
    ASTa increased 7% 13%
    Headache 7% 9%
    Asthenia 3% 6%
    Edema 10% 6%
    Myalgia 7% 6%
    Pain 10% 6%
    ALT a increased 7% 6%
    Flu syndrome 10% 16%
    Cough increased 0% 6%
    Hypesthesia 0% 6%
    Rhinitis 7% 6%
    Respiratory disorder 7% 3%
    Gastritis 7% 0%
    Pharyngitis 7% 3%
    Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase

     

    Immunogenicity

    As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to HUMATROPE with the incidence of antibodies to other products may be misleading.

    In a clinical study with HUMATROPE during the first 6 months of HUMATROPE therapy in 314 naive patients, 1.6% developed specific antibodies to HUMATROPE (binding capacity ≥0.02 mg/L). None had antibody concentrations which exceeded 2 mg/L. Throughout 8 years of this same study, two patients (0.6%) had binding capacity >2 mg/L. Neither patient demonstrated a decrease in growth velocity at or near the time of increased antibody production. It has been reported that growth attenuation from pituitary-derived GH may occur when antibody concentrations are >1.5 mg/L.

    Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of HUMATROPE. Because these adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Severe Hypersensitivity Reactions – Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products

    Neurologic – Headaches (common in pediatric patients and occasional in adults)

    Skin – Increase in size or number of cutaneous nevi

    Endocrine – Gynecomastia

    Gastrointestinal – Pancreatitis

    Metabolic – New-onset type 2 diabetes mellitus

    Neoplasia – Leukemia has been reported in a small number of GH deficient pediatric patients treated with somatropin

    Drug Interactions
    Read more
  • HYGETROPIN 8iu*25vials cheap high for sale

    $350.00 $340.00

    Recombinant Human Growth Hormone ( rhGH ) for injection
    Somatropin ( rDNA origin )
    Amino Acid 191
    8iu x 25 vials 200iu Kit
    Straight from the Hygene BioPharm lab. Never stored in two locations.
    Guaranteeing the freshness of every batch

    Price is as per Kit

    Add to cart
  • IGF-1 10iu*10vials High pills for men and women

    $120.00 $115.00

    Igtropin®igf-1 lr3 100mcg*10VIALS,1000mcg/KIT (Namely 0.1mg/vial,10vials/kit,1mg/kit)

    Igtropin IGF-1 LR3 (1000 mcg) Long chain insulin like growth factor is a specialty protein that contains 83 amino acids.

    This formula will work to increase protein synthesis, promote fat loss and metabolism boosting benefits, increase glucose transport as well as RNA synthesis. This is a great performance enhancing drugs that leads to the transformation of fat into energy. This drug is powerful enough to actually cause Hypertrophy which is a splitting of ourselves.

    Add to cart
  • JINTROPIN 10iu*10vials

    $250.00
    Jintropin is a growth hormone. Jintropin works by stimulating growth in patients who do not make enough natural growth hormone.
    Products specifications
    Form Vial
    Unit 10x 1ml
    Strength/mL 10x 10 IU
    Substance Somatropin
    Manufacturer: GenSci
    Price is as per Kit
    Add to cart
  • Nandroxyl 250- 10ml/vial

    $40.00
    • Nandroxyl 250

      Injectable Anabolic Steroid
      Active substance: Nandrolone Decanoate
      Manufacturer: Kalpa Pharmaceuticals Ltd.
      Unit: 10 mL vial (250 mg/mL)

    Add to cart
  • Pregnyl (Chorionic Gonadotropin) 5000 I.U

    $170.00

    Pregnyl (Chorionic Gonadotropin) 5000 I.U Vials/injections:

    Pregnyl (Chorionic Gonadotropin) treating fertility problems in certain women who have not gone through menopause. Treating certain testicular development problems and stimulating the development of secondary sexual characteristics in certain patients.

    You can buy Pregnyl (Chorionic Gonadotropin) 5000 I.U injections online without prescription (No RX).

    product price is as: per Vial
    Minimum order quantity is: 1 Vial

    Add to cart
  • Primoxyl 100-10ml/vial

    $55.00
    • Drug Class: Anabolic Steroid (for intramuscular injection)
    • Active Life: 10-14 days
    • Average Dose: Men 350-600 mg/week, Women 100 mg/week
    • Liver Toxicity: Low
    • Aromatization rate: None
    • DHT Conversion: None
    • Decrease HPTA function: Yes
    • Anabolic/ Androgenic rate: 88:44
    • Active Substance:

      Methenolone Enanthate 100mg/ml

     

    Add to cart
  • Rexogin 50 10x 1ml ampule ( 1ml = 50mg )

    $35.00

    Brand Name: Rexogin 50
    Also Known As: GP Stan 50, Stanodex 50, Stanaplex 50, Stanol, Stanabo, Winstrol Depot, Inject Stanozolol
    Manufacturer: Alpha Pharma, India.

    Active Ingredient: Stanozolol
    Quantity: 10x 1ml ampule ( 1ml = 50mg )

    Price is Per Kit

    Add to cart
  • Rexogin 50 10x 1ml ampule ( 1ml = 50mg )

    $80.00 $75.00

    Alpha Pharma Healthcare Supply: 10 x 1ml Ampoule. Contents: Stanozolol 50mg/ml

    Winstrol is a very popular oral or injectable anabolic-androgenic steroid. It ranks up there with Deca and Dianabol as the most widely used and abused drug by competitive athletes.

    Stanozolol is commonly referred to as Winny (Winstrol). Winstrol comes in two forms as mentioned above – both oral and injectable. The injections are the same methylated compound as the oral form of the drug. However, due to this feature, it cannot be esterified for time release. Winstrol has a short active life of around eight hours.

    Winstrol counteracts estrogenic side effects such as gyno and water retention – another quality which makes it attractive to the athlete seeking lean mass gains. Winstrol is a 5-alpha reduced substrate. 5-alpha reduction breaks the double bond between positions 4 and 5, which is what is required for aromatase to convert to estrogen. Aromatase is the primary enzyme used for the manufacturing of estrogen within the male body. For avoiding gyno, Winstrol is well suited.

    Since Winstrol is not capable of converting into estrogen, anti-estrogen ancillary drugs such as Nolvadex or Clomid are not necessary when using this steroid. Gyno will not be a concern for even the most sensitive individuals when using this steroid. Winstrol is excellent for lean gains since water retention is reduced when using this steroid. This is due to the fact that estrogen is the cause of water retention. It is excellent to use among athletes who are seeking for a combination of both strength and speed.

    Another point about Stanozolol is its supposed anti-progestagenic effects. Winstrol is said to bind and compete for a position at the progesterone receptor in much the same way that Clomid or Nolvadex does at the estrogen receptor. This is said to cause Winstrol to inhibit progestagenic effects. Progesterone does play a role in the development of gyno since it can aggravate estrogenic side-effects by agonizing estrogen and it also plays a role in gyno.

    Winstrol, like Dianabol, should not be used for extended periods of time since it is a 17-alpha-alkylated substance (oral only, does not apply to injectable), using it for much longer than 4-6 weeks is not advisable. Some athletes have been known to use it for eight weeks or even longer, but elevated liver values are a possibility if this is the case. For the sake of safety, such a long length of use is not recommended. 4-6 weeks will give the user good results and will add a boost to his or her steroid cycle, especially if stacked with a longer acting injectable ester. The reason for quick results with Winstrol is due to its short active life and combined with a greater frequency of injection or oral consumption, results are fairly quick. Dianabol is also used for this purpose.

    When using Winstrol, many of the usual side effects are rare. These include acne, water retention, high blood pressure, and aromatization leading to gyno. Winstrol does not convert to DHT and it results in very minimal suppression of the HPTA. However, since it is a 17-alpha-alkylated substrate, liver toxicity is a concern in high doses of Winstrol or when used for extended periods of time. However, it is slightly less hepatoxic than most other 17-AA steroids. Elevation in liver values is nevertheless common with Winstrol if used for extended periods of time or at high doses.

    The normal dosage for men is between 30-70 mg per day for the tablets and 25-50 mg per day for the injectable version of Winstrol. Winstrol is often combined with other steroids depending on what the personal goals of the athlete are. To gain muscle mass (bulking) Winstrol is best combined with a stronger androgen such as Testosterone. This will give the cycle a good anabolic effect while minimizing estrogenic activity. This results in excellent increases in lean muscle mass, as opposed to the more common bulking cycle which greatly increases muscle mass while also increasing water retention and some gains in fat. To lose fat (cutting), Winstrol is best combined with a non-aromatizing androgen such as Trenbolone or Halotestin. This combination can create a strongly defined, hard look. This is a very attractive look sought out by many bodybuilders.

    Woment should take around 5-10 mg daily for the recommended length of time of 4-6 week

    Add to cart
  • TAITROPIN 10iu*10vials High for adults

    $130.00 $125.00

    TAITROPIN HGH 10iu x 10vial+ 10 x 2ml Injection solvent ample

    Price is as per Kit

    Add to cart

Showing all 13 results